keyword
MENU ▼
Read by QxMD icon Read
search

Advanced lung cancer

keyword
https://www.readbyqxmd.com/read/29241190/circrna-expression-profile-in-early-stage-lung-adenocarcinoma-patients
#1
Jiangmin Zhao, Le Li, Qian Wang, Hongxiu Han, Qing Zhan, Ming Xu
BACKGROUND/AIMS: Lung adenocarcinoma, a form of non-small cell lung cancer with high lethality at an advanced stage, is becoming more common in women, non- or never-smokers, and even young adults. At present, there are still no effective early diagnosis methods for patients to be cured in a timely manner. Circular RNAs (circRNAs), which are stable and conserved non-coding RNA in mammalian cells, have been reported to be widely involved in the processes of cancer disease. However, it is still a puzzle as to which specific circRNAs are involved in the development of early-stage lung adenocarcinoma...
December 12, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29240878/pulmonary-sarcomatoid-carcinoma-an-analysis-of-a-rare-cancer-from-the-surveillance-epidemiology-and-end-results-database
#2
Mohamed Rahouma, Mohamed Kamel, Navneet Narula, Abu Nasar, Sebron Harrison, Benjamin Lee, Brendon Stiles, Nasser K Altorki, Jeffrey L Port
OBJECTIVES: Pulmonary sarcomatoid carcinoma (PSC) is a rare malignant neoplasm that accounts for a small percentage of non-small-cell lung carcinoma (NSCLC). At least 10% of PSCs has a spindle and/or giant cell component, which is often associated with a poor prognosis. We reviewed the Surveillance, Epidemiology, and End Results (SEER) database for the clinicopathological characteristics and surgical outcomes of PSCs. METHODS: The SEER database (1973-2013) was queried for PSC...
December 11, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29239731/practice-patterns-and-outcomes-for-pemetrexed-plus-platinum-doublet-as-neoadjuvant-chemotherapy-in-adenocarcinomas-of-lung-looking-beyond-the-usual-paradigm
#3
V Noronha, S Zanwar, A Joshi, V M Patil, A Mahajan, A Janu, J P Agarwal, P Bhargava, A Kapoor, K Prabhash
AIMS: Neoadjuvant chemotherapy (NACT) is the standard of care in non-small cell lung cancers (NSCLC) with locally advanced N2 disease. There is a scarcity of data for the pemetrexed-platinum regimen as NACT. Also, apart from N2 disease, the role of NACT in locally advanced NSCLCs for tumour downstaging is unclear. MATERIALS AND METHODS: Non-metastatic adenocarcinomas of lung treated with pemetrexed-platinum-based NACT were analysed. The patients with locoregionally advanced N2 disease and those who were borderline candidates for upfront definitive treatment were planned for NACT after discussion in a multidisciplinary clinic...
November 24, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29239189/-immunotherapy-in-the-treatment-of-lung-cancer
#4
O Fiala, O Šorejs, M Pešek, J Fínek
BACKGROUND: Lung cancer occupies the leading position of cancer incidence and mortality worldwide, including in the Czech Republic. Despite significant advances in systemic oncology treatments, lung cancer still has the worst prognosis, which is driving the need for innovative therapies and methods to treat this disease. Immunotherapy is a developing area of systemic oncology treatment, which has recently begun to be significantly applied to patients with lung carcinoma. The most useful type of immunotherapy currently employs checkpoint inhibitors, including CTLA-4 inhibitors (ipilimumab and tremelimumab) and PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, durvalumab, and avelumab)...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29239002/pharmacokinetics-of-osimertinib-in-chinese-patients-with-advanced-nsclc-a-phase-1-study
#5
Hongyun Zhao, Junning Cao, Jianhua Chang, Zhenxian Zhang, Li Yang, Jia Wang, Mireille Cantarini, Li Zhang
Osimertinib is an oral, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing and T790M resistance mutations. The study's (NCT02529995) primary objective was to characterize the pharmacokinetics (PK) of osimertinib and its metabolites in Chinese patients enrolled in China. PK was assessed following single and multiple doses of 40 or 80 mg osimertinib once daily. Patients were aged ≥ 18 years with locally advanced or metastatic EGFR-TKI-sensitizing (EGFRm) non-small cell lung cancer and World Health Organization performance status of 0/1, who had progressed following prior EGFR-TKI...
December 14, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29238696/identification-of-clinically-approved-drugs-indacaterol-and-canagliflozin-for-repurposing-to-treat-epidermal-growth-factor-tyrosine-kinase-inhibitor-resistant-lung-cancer
#6
Hongjian Li, Christy Wing-Sum Tong, Yee Leung, Man-Hon Wong, Kenneth Kin-Wah To, Kwong-Sak Leung
In advanced lung cancer, epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) have extraordinary clinical efficacy. However, their usefulness is severely compromised by drug resistance mediated by various mechanisms, the most important of which is the secondary EGFR T790M mutation. The mutation blocks the binding of EGFR TKIs to the receptor kinase, thereby abolishing the therapeutic efficacy. In this study, we used our free and open-source protein-ligand docking software idock to screen worldwide approved small-molecule drugs against EGFR T790M...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29238207/advances-in-t-cell-checkpoint-immunotherapy-for-head-and-neck-squamous-cell-carcinoma
#7
REVIEW
Xinmeng Qi, Bo Jia, Xue Zhao, Dan Yu
Head and neck squamous cell carcinoma (HNSCC) has been found to be a complex group of malignancies characterized by their profound immunosuppression and high aggressiveness. In most cases of advanced HNSCC, treatment fails to obtain total cancer cure. Efforts are needed to develop new therapeutic approaches to improve HNSCC outcomes. In this light, T-cells "immune checkpoint" has attracted much attention in cancer immunotherapy. It has been broadly accepted that inhibitory T-cell immune checkpoints contribute to tumor immune escape through negative immune regulatory signals (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], programmed cell death 1 [PD-1], B7-H3, and B7-H4, etc)...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29238168/the-role-of-maintenance-therapy-in-the-treatment-of-elderly-non-small-cell-lung-cancer-patients-a-meta-analysis-of-randomized-controlled-trials
#8
Liangzhe Zhang, Shugeng Gao, Jie He
Purpose: Maintenance therapy is an effective treatment strategy for advanced non-small-cell lung cancer (NSCLC). We aim to investigate whether age would affect the efficacy of maintenance therapy in the treatment of advanced NSCLC. Materials and methods: Relevant trials were identified by searching electronic databases and conference meetings. Prospective randomized controlled trials assessing maintenance therapy in elderly patients with advanced NSCLC were included...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29237953/quantitative-determination-of-tumor-platinum-concentration-of-patients-with-advanced-breast-lung-prostate-or-colorectal-cancers-undergone-platinum-based-chemotherapy
#9
Hesameddin Mostaghimi, Ali Reza Mehdizadeh, Mohammad Jahanbakhsh, Amir Reza Dehghanian, Ramin Askari
CONTEXT: Previous studies have reported direct relationship between tumor reduction and its platinum concentration following platinum-based (Pt-based) chemotherapy. However, quantitative data of tumor platinum concentration have not yet been reported for the most common cancers. AIMS: Determination of tumor platinum concentration of breast, lung, prostate, and colorectal cancers after Pt-based chemotherapy; and evaluation of the influence of chemo drug type, chemotherapy regimen, and time lapse from last chemotherapy on tumor platinum concentration...
October 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29237381/targeting-fgfr-with-bgj398-in-breast-cancer-effect-on-tumor-growth-and-metastasis
#10
Ana Sahores, Maria May, Gonzalo Sequeira, Cynthia Fuentes, Britta Jacobsen, Claudia Lanari, Caroline Ana Lamb
BACKGROUND: Endocrine resistance and metastatic dissemination comprise major clinical challenges for breast cancer treatment. The fibroblast growth factor receptor family (FGFR) consists of four tyrosine kinase transmembrane receptors, involved in key biological processes. Genomic alterations in FGFR have been identified in advanced breast cancer and thus, FGFR are an attractive therapeutic target. However, the efficacy of FGFR inhibitors on in vivo tumor growth is still controversial...
December 13, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/29236592/sequencing-of-postoperative-radiotherapy-and-chemotherapy-for-locally-advanced-or-incompletely-resected-non-small-cell-lung-cancer
#11
Samual Francis, Andrew Orton, Greg Stoddard, Randa Tao, Ying J Hitchcock, Wallace Akerley, Kristine E Kokeny
Purpose Although several feasibility studies have demonstrated the safety of adjuvant concurrent chemoradiotherapy (CRT) for locally advanced or incompletely resected non-small-cell lung cancer (NSCLC), it remains uncertain whether this approach is superior to sequential chemotherapy followed by postoperative radiotherapy (C→PORT). We sought to determine the most effective treatment sequence. Patients and Methods Using the National Cancer Database, we selected two cohorts of patients with nonmetastatic NSCLC who had received at least a lobectomy followed by multiagent chemotherapy and radiotherapy; cohort one included patients with R0 resection and pN2 disease, whereas cohort two included patients with R1-2 resection regardless of nodal status...
December 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29235457/serum-metabolic-profile-alteration-reveals-response-to-platinum-based-combination-chemotherapy-for-lung-cancer-sensitive-patients-distinguished-from-insensitive-ones
#12
Shan Xu, Yanping Zhou, Hui Geng, Dandan Song, Jing Tang, Xianmin Zhu, Di Yu, Sheng Hu, Yanfang Cui
Most lung cancers are diagnosed at fairly advanced stages due to limited clinical symptoms. Platinum-based chemotherapy, either as single regimen or in combination with radiation, is one of the major recommendations for the patients. Earlier evaluation of the effectiveness of the chemotherapies is critical for developing better treatment plan given the toxicity of the chemotherapeutic reagents. Drug efficacy could be reflected in the systemic metabolism characteristics though knowledge about which remains scarce...
December 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29234363/shenfu-injection-adjunct-with-platinum-based-chemotherapy-for-the-treatment-of-advanced-non-small-cell-lung-cancer-a-meta-analysis-and-systematic-review
#13
REVIEW
Ailing Cao, Hailang He, Mengxin Jing, Beibei Yu, Xianmei Zhou
Platinum-based chemotherapy is one of the standard treatments for non-small-cell lung cancer (NSCLC), while its high toxicity and limited clinical effects raise big concerns. Shenfu injection (SFI) has been commonly used as an adjutant chemotherapy drug for NSCLC in China. We ascertained the beneficial and adverse effects of SFI in combination with platinum-based chemotherapy for advanced NSCLC by using meta-analysis methods. The randomized controlled trials (RCTs) involving advanced NSCLC treatment with SFI plus platinum-based chemotherapy versus chemotherapy alone were searched on 6 medical databases up to February 2017...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29233789/predictive-performance-of-four-programmed-cell-death-ligand-1-assay-systems-on-nivolumab-response-in-previously-treated-patients-with-non-small-cell-lung-cancer
#14
Daichi Fujimoto, Yuki Sato, Keiichiro Uehara, Kaori Ishida, Junya Fukuoka, Takeshi Morimoto, Hayato Kawachi, Ryobu Mori, Munehiro Ito, Shunsuke Teraoka, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Yukihiro Imai, Keisuke Tomii
INTRODUCTION: Nivolumab has demonstrated efficacy against metastatic non-small cell lung cancer (NSCLC). Four programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) assay systems are available for identification of responders among patients with NSCLC, and these assays show some differing characteristics. Accordingly, in this study, we evaluated the ability of these assays to identify responders to nivolumab therapy. METHODS: We retrospectively analyzed patients with previously treated advanced NSCLC, who received nivolumab between January 2016 and September 2016...
December 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29230123/molecular-targets-in-non-small-cell-lung-cancer
#15
REVIEW
Ryan Griffin, Robert A Ramirez
Background: Lung cancer is the second most common cancer in the United States among men and women, and it is the most common cause of cancer-related death. Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases. Historically, patients with metastatic NSCLC received similar cytotoxic chemotherapy regimens. Genotyping studies have revealed genetic/molecular abnormalities in lung cancer. These driver mutations render a cancer dependent on that specific mutation's biochemical pathway for its growth and survival...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29228697/egfr-mutation-smoking-and-gender-in-advanced-lung-adenocarcinoma
#16
Chien-Hua Tseng, Chun-Ju Chiang, Jeng-Sen Tseng, Tsung-Ying Yang, Kuo-Hsuan Hsu, Kun-Chieh Chen, Chih-Liang Wang, Chih-Yi Chen, Sang-Hue Yen, Chun-Ming Tsai, Ming-Shyan Huang, Chao-Chi Ho, Chong-Jen Yu, Ying-Huang Tsai, Jin-Shing Chen, Teh-Ying Chou, Ming-Hsun Tsai, Hsuan-Yu Chen, Kang-Yi Su, Jeremy J W Chen, Huei-Wen Chen, Sung-Liang Yu, Tsang-Wu Liu, Gee-Chen Chang
Purpose: In the current targeted therapy era, information on the effect of smoking in epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results: In total, 11,678 adenocarcinoma patients were enrolled. Of these, 33.3% and 91.8% of male and female patients were non-smokers, respectively. An increased amount of smoking (P < 0.001 for trend), fewer smoke-free years (P < 0.001 for trend), and younger age of smoking initiation (P = 0...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228680/long-noncoding-rna-miat-promotes-non-small-cell-lung-cancer-proliferation-and-metastasis-through-mmp9-activation
#17
I-Lu Lai, Chin-An Yang, Pei-Chin Lin, Wen-Ling Chan, Ya-Ting Lee, Ju-Chen Yen, Ya-Sian Chang, Jan-Gowth Chang
Long noncoding RNAs (lncRNAs) play crucial roles in carcinogenesis. Myocardial infarction-associated transcript (MIAT), originally isolated as a candidate gene for myocardial infarction, has been found to act as an oncogene in chronic lymphocytic leukaemias and neuroendocrine prostate cancer (NEPC); however, little is known about its expression pattern, biological function, and underlying mechanism in non-small cell lung cancer (NSCLC). In this study, we observed that MIAT expression was upregulated in NSCLC, and its overexpression was associated with advanced tumor stage...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228627/increased-jab1-cops5-is-associated-with-therapeutic-response-and-adverse-outcome-in-lung-cancer-and-breast-cancer-patients
#18
Junna Hou, Guohong Liu, Yufen Yuan, Dong Wang, Pengfei Jiao, Lihua Xing, Yunbao Pan
Adjuvant chemotherapy has been established as standard treatment for advanced cancer among multidisciplinary therapies. A simple and instructive biomarker for therapeutic response and recurrence is needed to evaluate the therapeutic effect. Jab1/COPS5 level has been shown to be associated with tumor progression and poor outcomes in many types of cancer patients. This study aims to further evaluate the clinical and prognostic value of Jab1/COPS5 level as a biomarker in lung and breast cancer patients receiving adjuvant chemotherapy...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228559/initial-experience-of-anti-pd1-therapy-with-nivolumab-in-advanced-hepatocellular-carcinoma
#19
Duan Feng, Xie Hui, Lu Shi-Chun, Bai Yan-Hua, Cui Li, Li Xiao-Hui, Yan Jie-Yu
Purpose: To evaluate efficacy and safety of anti-PD1 therapy with nivolumab for treatment of advanced hepatocellular carcinoma (HCC). Methods: From Jan 2016 to Jan 2017, eleven cases of HCC (average age of 51.8-year), 4 at stage B and 7 at stage C, according to Barcelona Clinic Liver Cancer staging, were treated with nivolumab. There were 4 patients with lung metastasis, 1 with portal vein tumor thrombus, 1 with abdominal metastasis and 1 with bone metastasis. The protocol was nivolumab, 3 mg/kg, on day 1, q3w...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29227119/-molecular-pathology-of-lung-cancer-in-routine-diagnostic-practice-2017-update
#20
Radoslav Matěj, Zdeněk Rohan, Kristýna Němejcová, Pavel Dundr
The group of non-small cell lung carcinomas includes tumors that are variable at the clinical, histopathological and molecular levels. Advances in the understanding of molecular pathology of lung adenocarcinomas in particular led to changes in their histopathological classification and treatment. Patients diagnosed with lung adenocarcinoma harboring specific mutations benefit from the administration of specific targeted therapy. Analysis of EGFR gene mutations and ALK rearrangement in lung adenocarcinomas are already routinely performed and are closely related to the indication for the administration of tyrosinkinase inhibitors...
2017: Ceskoslovenská Patologie
keyword
keyword
36943
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"